An appraisal of the evidence underlying performance measures for community-acquired pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 11, 2011, Pages 1454-1462

  Wilson, Kevin C ^a   Schünemann, Holger J ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Antiinfective agents; Blood specimen collection; Influenza vaccines; Pneumococcal vaccines; Smoking cessation

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC THERAPY; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; FLU LIKE SYNDROME; HEALTH CARE QUALITY; HUMAN; INFLUENZA; MEDICAID; MEDICARE; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; VACCINATION;

ANTI-BACTERIAL AGENTS; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA; QUALITY INDICATORS, HEALTH CARE; RISK; SMOKING CESSATION; UNITED STATES;

EID: 79957936572     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201009-1451PP     Document Type: Review

References (102)

1. Specification Manual for National Hospital Quality Measures. Version 3.1a. [accessed 2010 Sept 6]. Available from: http://www.jointcommission.org/ specifications-manual-for-national-hospital-inpatient-quality-measures/
2. Principles Respecting Joint Commission Core Performance Measurement Activities. [accessed 2010 Sept 6] Available from: http://www.jointcommission. org/assets/1/18/Attach-A-Principles-Review.pdf
3. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-998.
4. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, et al. WHO rapid advice guidelines for pharmacological management of sporadic infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7:21-31. (Pubitemid 44932137)
5. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
6. Schunemann HJ, Vist GE, Jaeschke R, Kunz R, Cook DJ, Guyatt GH. Grading recommendations. In: Guyatt G, Rennie D, Meade MO, Cook DJ, editors. Users' guides to the medical literature. 2nd ed. New York: McGraw-Hill; 2008. pp. 679-701.
7. GRADEpro. [Computer program]. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
8. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;1:CD000422.
9. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48-58.
10. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-2677.
11. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001;19: 4780-4790. (Pubitemid 32800764)
12. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000;1:1.
13. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine: metaanalysis. Can Fam Physician 1999;45:2381-2393.
14. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results of randomized controlled trials. Vaccine 2004;22:3214-3224. (Pubitemid 39037227)
15. Honkanen PO, Keistenen T, Miettenen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493-2500. (Pubitemid 29314440)
16. Onyemelukwe GC, Leinoen M, Makela H, Greenwood BM. Response to pneumococcal vaccination in normal and post-infected Nigerians. J Infect 1985;11:139.
17. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001; 161:2099-2104.
18. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084. (Pubitemid 28016230)
19. Rigotti N, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev 2007;3: CD001837.
20. Barlow G, Nathwani D, Williams F, Ogston S, Winter J, Jones M, Slane P, Myers E, Sullivan F, Stevens N, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. Thorax 2007;62:67.
21. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865.
22. Metersky ML, Sweeney TA, Getzow MB, Siddiqui F, Nsa W, Bratzler DW. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours. Chest 2006;130:16-21. (Pubitemid 44116837)
23. Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008;149:29-32.
24. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008;168:351-356. (Pubitemid 351347125)
25. Pines JM, Hollander JE, Lee H, Everett WW, Uscher-Pines L, Metlay JP. Emergency department operational changes in response to pay-for-performance and antibiotic timing in pneumonia. Acad Emerg Med 2007;14:545.
26. Drake DE, Cohen A, Cohn J. National hospital antibiotic timing measures for pneumonia and antibiotic overuse. Qual Manag Health Care 2007;16:113.
27. Nicks BA, Manthey DE, Fitch MT. The Centers for Medicare and Medicaid Services (CMS) community-acquired pneumonia core measures lead to unnecessary antibiotic administration by emergency physicians. Acad Emerg Med 2009;16:184.
28. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation is community-acquired pneumonia. Chest 2006;130:11.
29. Houck PM, Bratzler DW, Niederman M, Bartlett JG. Pneumonia treatment process and quality. Arch Intern Med 2002;162:843.
30. McGarvey RN, Harper JJ. Pneumonia mortality reduction and quality improvement in a community hospital. QRB Qual Rev Bull 1993;19: 124.
31. Bruns AH, Oosterheert JJ, Hustinx WN, Gaillard CA, Hak E, Hoepelman AI. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2009;28:913.
32. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002;162:682-688. (Pubitemid 34226395)
33. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644. (Pubitemid 38392978)
34. Mandell LA, Wunderink RG, Anzueta A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America, American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
35. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730-1754.
36. Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menendez R, Lopardo G, Torres A, Rossi P, Ramirez JA. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results. Arch Intern Med 2009;169:1515-1524.
37. McCabe C, Kirschner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009;169:1525-1531.
38. Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA, Penarroja G, Camps M, Estruch R, Sanchez M, Menendez R, et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008;32:892-901.
39. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006; 119:859-864. (Pubitemid 44415614)
40. Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006;119:865-871. (Pubitemid 44415611)
41. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004;117:726-731. (Pubitemid 39482525)
42. Villari P, Manzoli L, Boccia A. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 2004;22:3475-3486. (Pubitemid 39078767)
43. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007;2:CD001269.
44. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006;CD004876.
45. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA. An official ATS statement: grading the quality of evidence and strength or recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-614. (Pubitemid 44330555)
46. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:342-347. (Pubitemid 38134812)
47. Campbell SG, Marrie TJ, Antsey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142-1150. (Pubitemid 36444372)
48. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
49. Ward AC. The role of causal criteria in causal inferences: Bradford-Hill's "aspects of association." Epidemiol Perspect Innov 2009;6:2.
50. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-195.
51. Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. Bethesda, MD: National Institute of Allergy and Infectious Diseases; 1980. pp. 184-194.
52. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, Reid RD. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-194. (Pubitemid 8027923)
53. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: a pilot study. Chest 1987;92:204.
54. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355:2106-2111. (Pubitemid 30364659)
55. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP, Delormas P, Micoud M. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions. Rev Epidemiol Sante Publique 1985;33:437-444. (Pubitemid 16164941)
56. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17:2493-2500. (Pubitemid 29314440)
57. Kaufman P. Pneumonia in old age; active immunization against pneumonia with pneumococcal polysaccharide; results of a six year study. Arch Intern Med 1947;79:518.
58. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986;22:807-813. (Pubitemid 16071302)
59. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-290. (Pubitemid 27459254)
60. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987;136:361-365. (Pubitemid 17015980)
61. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, Kalin M. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399-403. (Pubitemid 28064163)
62. Riley ID, Tarr PI, Andrews M, Pfeiffer M, Howard R, Challands P, Jennison G. Immunization with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977;1:1338-1341. (Pubitemid 8127683)
63. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PH, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-1327. (Pubitemid 17030409)
64. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-2616. (Pubitemid 8274516)
65. Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung diseasethe effect of ongoing, systematic steroid treatment. Vaccine 2006;24: 1408-1412. (Pubitemid 43222051)
66. Zhogolev SD, Mosiaquin VD, Demidovich VA, Mel'nichenko PI, Ogarkov PI. Efficacy of pneumococcal vaccine in military units. Zh Mikrobiol Epidemiol Immunobiol 2003;2:36-42.
67. Bolman C, de Vries H, van Breukelen G. A minimal-contact intervention for cardiac inpatients: long-term effects on smoking cessation. Prev Med 2002;35:181-192.
68. Chouinard MC, Robichaud-Ekstrand S. The effectiveness of a nursing inpatient smoking cessation program in individuals with cardiovascular disease. Nurs Res 2005;54:243-254. (Pubitemid 41097416)
69. Croghan GA, Croghan IT, Frost MA, Sloan JA, Novotny PJ, Nelson MA. Smoking cessation interventions and post-operative outcomes in esophageal and lung cancer patients. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March, Prague, Czech Republic. 2005:139.
70. Hajek P, Taylor TZ, Mills P. Brief intervention during hospital admission to help patients to give up smoking after myocardial infarction and bypass surgery: randomized controlled trial. BMJ 2002; 324:87-89. (Pubitemid 34073139)
71. Hennrikus DJ, Lando HA, McCarty MC, Klevan D, Holtan N, Huebsch JA, Jestus S, Pentel PR, Pine D, Sullivan S, et al. The TEAM project: the effectiveness of smoking cessation intervention in hospital patients. Prev Med 2005;40:249-258. (Pubitemid 39468586)
72. Molyneux A, Lewis S, Leivers U, Anderton A, Antioniak M, Brackenridge A, Nilsson F, McNeill A, West R, Moxham J, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counseling alone, and minimal intervention on smoking cessation in hospital patients. Thorax 2003;58:484-488. (Pubitemid 36714008)
73. Nagle AL, Hensley MJ, Schofield MJ, Koschel AJ. A randomized controlled trial to evaluate the efficacy of a nurse-provided intervention for hospitalized smokers. Aust N Z J Public Health 2005; 29:285-291. (Pubitemid 40823625)
74. Pelletier JG, Moisan JT. Smoking cessation for hospitalized patients: a quasi-experimental study in Quebec. Can J Public Health 1998;89: 264-269. (Pubitemid 28454431)
75. Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Addict 1991; 26:107-119.
76. Griebel B, Wewers ME, Baker CA. The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. Oncol Nurs Forum 1998;25:897-902.
77. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukada K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-1663.
78. Couch RB, Quarles JM, Cate TR, Zahradnik. Clinical trials with live, cold-resortment influenza virus vaccines. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza. Proceedings of a Viratek-UCLA symposium (Keystone, CO, 1985). UCLA symposia on molecular and cellular biology. New York: Alan R. Liss; 1986. pp. 223-241.
79. Eddy TS, Davies NA. The effect of vaccine on a close epidemic of Hong Kong influenza. S Afr Med J 1970;44:214-216.
80. Edmondson KW, Graham DS, Warburton MF. A clinical trial of influenza vaccine in Canberra. Med J Aust 1970;2:6-13.
81. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J InfectDis 1994;169:68-76.
82. Hammond ML, Ferris AA, Faine S, McAvan T. Effective protection against influenza after vaccination with subunit vaccine. Med J Aust 1978;1:301-303. (Pubitemid 8371637)
83. Hoskins TW, Davies JR, Allchin A, Miller CL, Pollock TM. Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain. Lancet 1973;2:116-120.
84. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997;15:1114-1122. (Pubitemid 27357195)
85. Leibovitz A, Coultrip RL, Kilbourne ED, Legters LJ, Smith CD, Chin J, Schulman JL. Correlated studies of a recombinant influenza-virus vaccine: IV. Protection against naturally occurring influenza in military trainees. J Infect Dis 1971;124:481-487.
86. Mair HJ, Sansome DA, Tillett HE. A controlled trial of inactivated monovalent influenza A vaccines in general practice. J Hyg (Lond) 1974;73:317-327.
87. Maynard JE, Dull HB, Hanson ML, Feltz ET, Berger R, Hammes L. Evaluation of monovalent and polyvalent influenza vaccines during an epidemic of type A2 and B influenza. Am J Epidemiol 1968;87: 148-157.
88. Mixeu MA, Vespa GN, Forleo-Neto E, Toniolo-Neto J, Alves PM. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002;73:876-880. (Pubitemid 34994516)
89. Mogabgab WJ, Leiderman E. Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA 1970;211:1672-1676.
90. Monto AS, Miller FD, Maassab HF. Evaluation of an attenuated, cold-recombinant influenza B virus vaccine. J Infect Dis 1982;145:57-64. (Pubitemid 12212417)
91. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995; 333:889-893.
92. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-144. (Pubitemid 29323803)
93. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, Volvovitz F, Belshe RB, Treanor JJ. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995;171:1595-1599.
94. Rytel MW, Jackson LJ, Niebojewski RA, Haagensen JL, Rosenkranz MA. Field trial of live attenuated influenza A/B ("Alice"/R-75) vaccine. Am J Epidemiol 1977;105:49-55. (Pubitemid 8020095)
95. Slepuskin AN, Bobyleva TK, Russina AE, Vitkina BS, Ellengorn NS, Zdanov VM. Evaluation of the effectiveness of large-scale vaccination against influenza in the USSR. Bull World Health Organ 1967; 36:385-395.
96. Tannock GA, Bryce DA, Hensley MJ, Saunders NA, Gillett RS, Kennedy WS. Responses to one or two of a deoxycholate subunit influenza vaccine in a primed population. Vaccine 1984;2: 100-106.
97. Waldman RH, Coggins WJ. Influenza immunization: field trial on a university campus. J Infect Dis 1972;126:242-248.
98. Waldman RH, Bond JO, Levitt LP, Hartwig ED, Prather EC, Baratta RL, Neill JS, Small PA Jr. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull World Health Organ 1969;41:543-548.
99. Waldman RH, Mann JJ, Small PA Jr. Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine. JAMA 1969;207:520-524.
100. Weingarten S, Staniloff H, Ault M, Miles P, Bamberger M, Myer RD. Do hospital employees benefit for the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 1988;3:32-37.
101. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999;281:908-913. (Pubitemid 29124634)
102. Williams MC, Davignon L, McDonald JC, Pavilanis PV, Boudreault A, Clayton AJ. Trials of aqueous killed influenza vaccine in Canada, 1968-69. Bull World Health Organ 1973;49:333-340.